Specialty pipeline forecast as of June 2009

[chantell.reagan]

The following list represents specialty pipeline updates for June 2009 from DrugPipelineForecast.com. Please click on the product name to view update for individual products. To access DrugPipelineForecast, you must be a registered user of DrugManagementForum (click here to register)

AAT-IV - BLA filed (new entry in DrugPipelineForecast)

Actemra - positive Phase III data

Amigal - Phase III trial started

Armala - positive Phase III data

Arzerra - FDA advisory committee recommends drug; PDUFA date delayed

belatacept - positive Phase III data

BioVaxID - positive Phase III data

CP-690,550 - positive Phase III data

Ilaris (canakinumab) - FDA approved (removed from DrugPipelineForecast)

INCB18424 - Phase III to begin 8/09 (new entry in DrugPipelineForecast)

ipilimumab - positive Phase III data

JZP-6 - positive Phase III data

Kalbitor - NDA accepted, PDUFA date set

LB03002 - positive Phase III data

lestaurtinib - negative Phase III data

Lucassin - final portion of NDA filed

Krystexxa - FDA advisory board recommends drug

Mylinax - positive Phase III data

PEGylated interferon beta-1a - Phase III trials started

pixantrone - positive Phase III data; NDA completed with priority review requested

Prolia - FDA advisory board date set

Stimuvax - Phase III trials started

tesamorelin - NDA filed

VX-770 - Phase III trial started (new entry in DrugPipelineForecast)

Xarelto - positive Phase III data

Xiaflex - PDUFA date delayed

Zactima - positive Phase III data

Zunrisa - FDA rejects drug

For more information, or to search additional drugs, see DrugPipelineForecast.com